Fair Value Measurement - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) security	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of securities in unrealized loss position | security	20
Securities in continuous unrealized loss position, less than 12 months	$ 29,100,000
Securities in continuous unrealized loss position, less than 12 months, accumulated loss	46,300
Available-for-sale marketable securities	217,630,000	$ 128,599,000
Contingent liability fair value measurement gain	13,200,000	0	$ 0
Antares Pharma, Inc
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent liability fair value measurement gain	13,200,000
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale marketable securities	$ 0	$ 0